24.02
price down icon9.80%   -2.61
after-market After Hours: 24.02
loading
Vera Therapeutics Inc stock is traded at $24.02, with a volume of 2.71M. It is down -9.80% in the last 24 hours and down -19.75% over the past month.
See More
Previous Close:
$26.63
Open:
$25
24h Volume:
2.71M
Relative Volume:
3.29
Market Cap:
$1.73B
Revenue:
-
Net Income/Loss:
$-107.85M
P/E Ratio:
-10.87
EPS:
-2.21
Net Cash Flow:
$-106.82M
1W Performance:
-11.53%
1M Performance:
-19.75%
6M Performance:
-45.66%
1Y Performance:
-44.29%
1-Day Range:
Value
$22.34
$25.00
1-Week Range:
Value
$22.34
$27.68
52-Week Range:
Value
$22.34
$51.61

Vera Therapeutics Inc Stock (VERA) Company Profile

Name
Name
Vera Therapeutics Inc
Name
Phone
650-770-0077
Name
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-08-08
Name
Latest SEC Filings
Name
VERA's Discussions on Twitter

Compare VERA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VERA
Vera Therapeutics Inc
24.02 1.73B 0 -107.85M -106.82M -2.21
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-04-25 Initiated Wolfe Research Outperform
Jan-28-25 Initiated Goldman Buy
Nov-21-24 Initiated Wells Fargo Overweight
Oct-16-24 Initiated Scotiabank Sector Outperform
Jan-25-24 Initiated Oppenheimer Outperform
Jan-08-24 Initiated Cantor Fitzgerald Overweight
Dec-18-23 Initiated Raymond James Outperform
Nov-10-23 Upgrade Jefferies Hold → Buy
Aug-16-23 Initiated Guggenheim Buy
Jan-04-23 Downgrade Jefferies Buy → Hold
Jan-04-23 Downgrade Wedbush Outperform → Neutral
Jul-12-22 Initiated JP Morgan Overweight
May-02-22 Initiated H.C. Wainwright Buy
Apr-19-22 Initiated Wedbush Outperform
View All

Vera Therapeutics Inc Stock (VERA) Latest News

pulisher
12:47 PM

Vera Therapeutics (NASDAQ:VERA) Reaches New 1-Year LowWhat's Next? - MarketBeat

12:47 PM
pulisher
Mar 29, 2025

69,724 Shares in Vera Therapeutics, Inc. (NASDAQ:VERA) Bought by Raymond James Financial Inc. - Defense World

Mar 29, 2025
pulisher
Mar 26, 2025

Vera Therapeutics stock hits 52-week low at $25.97 By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Vera Therapeutics stock hits 52-week low at $25.97 - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Vera Therapeutics validates Fair Value bearish call with 42% decline By Investing.com - Investing.com UK

Mar 26, 2025
pulisher
Mar 26, 2025

Swiss National Bank Purchases 15,700 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World

Mar 26, 2025
pulisher
Mar 22, 2025

AlphaQuest LLC Takes Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World

Mar 22, 2025
pulisher
Mar 20, 2025

Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Charles Schwab Investment Management Inc. - Defense World

Mar 20, 2025
pulisher
Mar 17, 2025

Bank of New York Mellon Corp Acquires 7,895 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World

Mar 17, 2025
pulisher
Mar 14, 2025

Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load? - Simply Wall St

Mar 14, 2025
pulisher
Mar 14, 2025

Victory Capital Management Inc. Increases Stake in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Buy” by Analysts - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Vera Therapeutics (VERA) Expected to Announce Quarterly Earnings on Wednesday - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

Vera Therapeutics Growth Accelerates: 9 Strategic Hires Secure Equity Package Worth $2.3M - StockTitan

Mar 11, 2025
pulisher
Mar 11, 2025

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MENAFN.COM

Mar 11, 2025
pulisher
Mar 08, 2025

What is HC Wainwright’s Estimate for VERA FY2025 Earnings? - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much? - Seeking Alpha

Mar 07, 2025
pulisher
Mar 07, 2025

Cantor Fitzgerald Analysts Lower Earnings Estimates for VERA - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

JPMorgan Chase & Co. Has Lowered Expectations for Vera Therapeutics (NASDAQ:VERA) Stock Price - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Vera Therapeutics (NASDAQ:VERA) Price Target Cut to $71.00 by Analysts at JPMorgan Chase & Co. - Armenian Reporter

Mar 05, 2025
pulisher
Mar 04, 2025

Vera Therapeutics Getting Closer To Key Technical Benchmark - MSN

Mar 04, 2025
pulisher
Mar 03, 2025

Rhumbline Advisers Has $2.48 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World

Mar 03, 2025
pulisher
Mar 03, 2025

Q1 EPS Estimates for Vera Therapeutics Boosted by Wedbush - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

(VERA) On The My Stocks Page - news.stocktradersdaily.com

Mar 02, 2025
pulisher
Mar 02, 2025

What is Wedbush’s Forecast for VERA FY2029 Earnings? - Defense World

Mar 02, 2025
pulisher
Mar 01, 2025

Guggenheim Raises Vera Therapeutics (NASDAQ:VERA) Price Target to $61.00 - Defense World

Mar 01, 2025
pulisher
Feb 28, 2025

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewswire

Feb 28, 2025
pulisher
Feb 27, 2025

Wedbush Adjusts Price Target on Vera Therapeutics to $34 From $38, Maintains Neutral Rating - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Guggenheim raises Vera Therapeutics stock target to $61 - Investing.com India

Feb 27, 2025
pulisher
Feb 27, 2025

Can Vera Therapeutics Reveal New Immunology Pipeline Updates at Upcoming TD Cowen Conference? - StockTitan

Feb 27, 2025
pulisher
Feb 26, 2025

Optimistic Buy Rating for Vera Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Vera Therapeutics targets Q2 for IgAN drug results, FDA filing By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

Vera Therapeutics 2024 Loss Widens -February 26, 2025 at 08:53 am EST - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

Vera Therapeutics targets Q2 for IgAN drug results, FDA filing - Investing.com India

Feb 26, 2025
pulisher
Feb 26, 2025

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Feb 26, 2025
pulisher
Feb 26, 2025

Earnings Flash (VERA) Vera Therapeutics Posts Full Year 2024 Total Operating Expenses $167.2M - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

Earnings Flash (VERA) Vera Therapeutics Posts Full Year 2024 Net Loss $-2.75 a Share, vs. FactSet Est of $-2.90 Loss - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

Vera Therapeutics, Inc. Reports 2024 Business Highlights and Financial Results; On Track for Phase 3 ORIGIN Trial Results and FDA Submission for Atacicept in IgA Nephropathy - Nasdaq

Feb 26, 2025
pulisher
Feb 26, 2025

Can Vera's Breakthrough IgAN Therapy Disrupt the $5B Kidney Disease Market? Phase 3 Results Coming Q2 2025 - StockTitan

Feb 26, 2025
pulisher
Feb 20, 2025

Vera Therapeutics’ Atacicept Positioned for Growth Amid Market Overreaction to Otsuka’s Sibeprenlimab - TipRanks

Feb 20, 2025
pulisher
Feb 20, 2025

(VERA) Trading Advice - Stock Traders Daily

Feb 20, 2025
pulisher
Feb 19, 2025

Vera Therapeutics Inc (VERA) may enjoy gains as insiders got busy in the recent days - Knox Daily

Feb 19, 2025
pulisher
Feb 18, 2025

Cantor Fitzgerald maintains Overweight on Vera Therapeutics stock By Investing.com - Investing.com Nigeria

Feb 18, 2025
pulisher
Feb 18, 2025

Evercore ISI maintains Vera Therapeutics stock with $75 target By Investing.com - Investing.com Canada

Feb 18, 2025
pulisher
Feb 18, 2025

Evercore ISI maintains Vera Therapeutics stock with $75 target - Investing.com

Feb 18, 2025
pulisher
Feb 18, 2025

Vera Therapeutics weakness on Otsuka plans ‘makes no sense,’ says Wells Fargo - MSN

Feb 18, 2025
pulisher
Feb 16, 2025

Vera Therapeutics stock drops amid rival drug update - MSN

Feb 16, 2025
pulisher
Feb 15, 2025

Vera Therapeutics (NASDAQ:VERA) Hits New 1-Year LowWhat's Next? - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

Vera Therapeutics stock drops amid rival drug update By Investing.com - Investing.com Australia

Feb 15, 2025

Vera Therapeutics Inc Stock (VERA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):